Infertility Clinical Trial
Official title:
Comparison Between Stimulated Intrauterine Insemination Cycles and Unstimulated Intrauterine Insemination Cycles in Couples With Unexplained Infertility
Four hundred and fifty women with unexplained infertility will be divided into 3 equal groups using computer generated random numbers: Group 1 will have up to 4 stimulated IUI cycles, group 2 will have up to 4 unstimulated cycles, women who do not become pregnant after the 4 cycles in groups 1 and 2 will be advised to have regular intercourse at the expected time of ovulation. Group 3 will be the control group will be advised to have regular sexual intercourse at the time of ovulation for 6 months
Unexplained infertility is a common diagnosis encountered in the subfertility clinic; about
15-30% of infertile couples will be diagnosed as having unexplained infertility. Couples are
usually diagnosed as having unexplained infertility if the woman has ovulatory cycles,
patent tubes and the spouse has a normal semen analysis according to the world health
organisation criteria.
In the absence of an organic abnormality or a clear functional defect, couples with
unexplained infertility have been subjected to several empirical treatments including
intra-uterine insemination (IUI). The application of ovarian stimulation in IUI is
advocated, even if the woman has ovulatory cycles, to improve the pregnancy rates with IUI.
However, the application of ovarian stimulation has two main drawbacks: The increased
chances of a multiple pregnancy and ovarian hyperstimulation syndrome. To avoid these
complications unstimulated IUI cycles have been investigated. The objective of the study is
to evaluate the role of stimulated and unstimulated IUI cycles in the management of
unexplained infertility.
The study will be conducted in Cairo university hospitals and BeniSuef University hospitals
All patients with unexplained infertility attending both sites will be invited to
participate in the study. The study will be explained and only couples who sign written
consents will be included in the study.
Four hundred and fifty women with unexplained infertility will be divided into 3 equal
groups using computer generated random numbers: Group 1 will have up to 4 stimulated IUI
cycles, group 2 will have up to 4 unstimulated cycles, women who do not become pregnant
after the 4 cycles in groups 1 and 2 will be advised to have regular intercourse at the
expected time of ovulation. Group 3 will be the control group will be advised to have
regular sexual intercourse at the time of ovulation for 6 months On the 3rd day of
menstruation group 1 will have a vaginal ultrasound and will receive daily intramuscular 150
IU of human menopausal gonadotropins (hMG, Merional ®, IBSA, Lugano, Switzerland) starting
from the 3nd day of menstruation. On day 8 the ultrasound will be repeated and serum E2 will
be measured, hMG dose will be adjusted and continued and the frequency of ultrasound scans
will be individualized. HMG will be stopped when at least 2 follicles measuring 18 mm are
associated with serum E2 of 500-3000 Pg/mL, this was followed by the administration of 10000
IU of human chorionic gonadotropin (hCG; Choriomon®, IBSA) Women in group 2 will be asked to
test their morning urine specimen for luteinizing hormone daily starting 4 days before the
expected day of ovulation. This will be done using a qualitative kit. Intrauterine
insemination will be performed on the day after the surge in urinary excretion of
luteinizing hormone.
Women in group 3 will be asked to test their urine for luteinizing hormone by the same
method as group 2. They will be asked to have an intercourse on the day after the surge in
urinary excretion of luteinizing hormone and this will be repeated for 12 months.
Semen specimens for groups 1 and 2 will be evaluated and prepared for IUI within one hour
after collection. Semen will be diluted 1:2 (vol/vol) with HEPES-buffered Ham's F10 medium
containing 1.5 percent serum albumin. After centrifugation for 10 minutes, the pellets will
be resuspended and combined in 3 ml of the medium.
The sperm suspension will be centrifuged for 10 minutes, and the pellet was resuspended in
0.35 ml of medium. Approximately 0.05 ml will be used to determine the concentration and
motility of sperms. The remaining sample will be drawn into a shepherd catheter attached to
a 1 mL syringe and injected into the uterus.
The procedure will be repeated for up to 4 months in groups 1 and 2, if pregnancy does not
occur. Women who do not conceive after the 4 trials will be asked to check their urine for
luteinizing hormone using the ovulation detection kits and have an intercourse on the day
following the luteinizing hormone surge. This will be repeated for 8 months.
The pregnancy rates of the 3 groups will be compared after the 4 months and after one year.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03607409 -
Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
|
||
| Recruiting |
NCT02312076 -
GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles
|
Phase 4 | |
| Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
| Completed |
NCT03287479 -
Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®)
|
N/A | |
| Terminated |
NCT03522350 -
Randomized Trial Comparing EmbryoScope With EmbryoScope+.
|
N/A | |
| Completed |
NCT04496284 -
Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen
|
N/A | |
| Completed |
NCT03623659 -
pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts
|
N/A | |
| Completed |
NCT03895099 -
New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors
|
Phase 3 | |
| Active, not recruiting |
NCT04142112 -
Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation
|
N/A | |
| Completed |
NCT03152643 -
Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer
|
N/A | |
| Recruiting |
NCT03683771 -
Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
|
||
| Recruiting |
NCT03161119 -
Comparing Two Different Embryo Transfer Catheters
|
N/A | |
| Completed |
NCT04108039 -
Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.
|
N/A | |
| Completed |
NCT03678818 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)
|
N/A | |
| Completed |
NCT03678558 -
Oocyte Vitrification Aided With Cytochalasin B
|
N/A | |
| Completed |
NCT03678597 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB)
|
N/A | |
| Completed |
NCT03678571 -
Oocyte Vitrification Aided With Latrunculin A
|
N/A | |
| Completed |
NCT03678610 -
Handling Medium for ICSI With Ionomycin and Latrunculin A
|
N/A | |
| Completed |
NCT03678584 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA)
|
N/A | |
| Completed |
NCT03677492 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD)
|
N/A |